ES2568647T3 - Gotas oftálmicas para tratar infección ocular que contienen levofloxacino, sal del mismo o solvato del mismo, método de tratamiento de infección ocular, levofloxacino, sal del mismo o solvato del mismo, y su uso - Google Patents

Gotas oftálmicas para tratar infección ocular que contienen levofloxacino, sal del mismo o solvato del mismo, método de tratamiento de infección ocular, levofloxacino, sal del mismo o solvato del mismo, y su uso Download PDF

Info

Publication number
ES2568647T3
ES2568647T3 ES10846644.2T ES10846644T ES2568647T3 ES 2568647 T3 ES2568647 T3 ES 2568647T3 ES 10846644 T ES10846644 T ES 10846644T ES 2568647 T3 ES2568647 T3 ES 2568647T3
Authority
ES
Spain
Prior art keywords
levofloxacin
genus
ophthalmic solution
salt
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10846644.2T
Other languages
English (en)
Spanish (es)
Inventor
Takashi Nagano
Koji Sakanaka
Masatsugu Nakamura
Kouichi Kawazu
Hajime Ibuki
Kayoko Sakamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd, Daiichi Sankyo Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2568647T3 publication Critical patent/ES2568647T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ES10846644.2T 2010-02-25 2010-12-16 Gotas oftálmicas para tratar infección ocular que contienen levofloxacino, sal del mismo o solvato del mismo, método de tratamiento de infección ocular, levofloxacino, sal del mismo o solvato del mismo, y su uso Active ES2568647T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010040281 2010-02-25
JP2010040281 2010-02-25
PCT/JP2010/072685 WO2011104981A1 (ja) 2010-02-25 2010-12-16 レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する眼感染症治療用点眼剤、眼感染症の治療方法、レボフロキサシンもしくはその塩またはそれらの溶媒和物、ならびにその使用

Publications (1)

Publication Number Publication Date
ES2568647T3 true ES2568647T3 (es) 2016-05-03

Family

ID=44506417

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10846644.2T Active ES2568647T3 (es) 2010-02-25 2010-12-16 Gotas oftálmicas para tratar infección ocular que contienen levofloxacino, sal del mismo o solvato del mismo, método de tratamiento de infección ocular, levofloxacino, sal del mismo o solvato del mismo, y su uso

Country Status (16)

Country Link
US (1) US20120316158A1 (enExample)
EP (1) EP2540299B1 (enExample)
JP (3) JP5600056B2 (enExample)
KR (2) KR20130043611A (enExample)
CN (1) CN102770141A (enExample)
BR (1) BR112012021247A2 (enExample)
CA (1) CA2791190C (enExample)
EA (1) EA201290827A1 (enExample)
ES (1) ES2568647T3 (enExample)
MX (1) MX349603B (enExample)
MY (1) MY183483A (enExample)
NZ (1) NZ602126A (enExample)
PH (2) PH12012501674A1 (enExample)
SG (1) SG183427A1 (enExample)
TW (1) TWI488627B (enExample)
WO (1) WO2011104981A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2791190C (en) * 2010-02-25 2017-12-12 Santen Pharmaceutical Co., Ltd. Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and use thereof
CN103550144B (zh) * 2013-10-25 2015-10-14 深圳朗欧医药集团有限公司 盐酸左氧氟沙星组合物注射液及其制备方法
JP6363833B2 (ja) * 2013-11-22 2018-07-25 ナノシータ株式会社 薄膜状高分子構造体
CN104606198A (zh) * 2015-01-09 2015-05-13 周元铎 盐酸左氧氟沙星在制备防治家蚕细菌性败血病药中的应用
IT201900005280A1 (it) * 2019-04-05 2020-10-05 Ntc S R L Composizione otologica

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3038722B2 (ja) 1989-06-23 2000-05-08 日本電気株式会社 接合型電界効果トランジスタ
JP3192290B2 (ja) 1993-08-04 2001-07-23 カネボウ株式会社 ポリエステル製耐熱ボトル
US7629458B2 (en) * 2001-10-03 2009-12-08 Teva Pharmaceutical Industries Ltd. Preparation of levofloxacin and hemihydrate thereof
US7169792B2 (en) * 2001-11-30 2007-01-30 Lg Life Sciences Ltd. Method of treating bacterial infections using gemifloxacin or a salt thereof and a β-lactam antibiotic
WO2005000307A1 (en) * 2003-06-26 2005-01-06 Santen Pharmaceutical Co., Ltd. Ophthalmic composition containing quinolones and method of use
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
JP2009526003A (ja) * 2006-02-10 2009-07-16 パーリ・ファルマ・ゲーエムベーハー 吸入療法用噴霧状抗生物質
WO2008005276A2 (en) * 2006-06-30 2008-01-10 Directcontact Llc Growth factor delivery system containing antimicrobial agents
EP2143422A1 (en) * 2008-07-11 2010-01-13 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic compositions containing gemifloxacin for the treatment of ocular infections
CA2791190C (en) * 2010-02-25 2017-12-12 Santen Pharmaceutical Co., Ltd. Ophthalmic solution for treating ocular infection comprising levofloxacin or salt thereof or solvate of the same, method for treating ocular infection, levofloxacin or salt thereof or solvate of the same, and use thereof

Also Published As

Publication number Publication date
PH12012501674A1 (en) 2012-11-05
PH12016501747A1 (en) 2019-02-11
WO2011104981A1 (ja) 2011-09-01
US20120316158A1 (en) 2012-12-13
SG183427A1 (en) 2012-09-27
JP5600056B2 (ja) 2014-10-01
JP2013241464A (ja) 2013-12-05
EP2540299A4 (en) 2013-07-24
MX349603B (es) 2017-08-03
PH12016501747B1 (en) 2022-06-22
CA2791190C (en) 2017-12-12
JP5674882B2 (ja) 2015-02-25
JP2011195564A (ja) 2011-10-06
EP2540299A1 (en) 2013-01-02
BR112012021247A2 (pt) 2018-04-03
CN102770141A (zh) 2012-11-07
MY183483A (en) 2021-02-20
CA2791190A1 (en) 2011-09-01
AU2010346703A1 (en) 2012-09-20
JP2012162532A (ja) 2012-08-30
EP2540299B1 (en) 2016-04-13
NZ602126A (en) 2013-10-25
TW201129364A (en) 2011-09-01
HK1177887A1 (en) 2013-08-30
EA201290827A1 (ru) 2013-03-29
KR20130043611A (ko) 2013-04-30
TWI488627B (zh) 2015-06-21
KR20170070265A (ko) 2017-06-21
MX2012009844A (es) 2012-09-21

Similar Documents

Publication Publication Date Title
Leung et al. Bacterial conjunctivitis in childhood: etiology, clinical manifestations, diagnosis, and management
US20110294768A1 (en) Ophthalmic Suspension for Ocular Use
JP5674882B2 (ja) レボフロキサシンもしくはその塩またはそれらの溶媒和物を含有する結膜炎治療用点眼剤
O’Brien Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis
Pichichero Bacterial conjunctivitis in children: antibacterial treatment options in an era of increasing drug resistance
Sanders et al. Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis
HK1177887B (en) Eye drops for treating eye infection containing levofloxacin, salt thereof or solvate of same, method for treating eye infection, levofloxacin, salt thereof or solvate of same, and utilization thereof
Sharma et al. Antimicrobial agents for ocular use: bacterial, fungal, viral, and protozoal infections
ES2273872T3 (es) Gatifloxacino como inhibidor de la produccion de citoquinas.
Adamiec-Mroczek et al. Efficient antiseptic prophylaxis in the era of antibiotic resistance
Post et al. Levofloxacin in everyday ophthalmic practice–review
AKANDA et al. Efficacy of Perioperative Oral Antibiotics in the Prevention of Acute Infective Endophthalmitis after SICS
HK1178045A (en) Eye drops for treating eye infection containing levofloxacin, salt thereof or solvate of same, method for treating eye infection, levofloxacin, salt thereof or solvate of same, and utilization thereof
Laxson 13 Chapter Osmotic Agents
RU2330633C1 (ru) Способ лечения язв роговицы синегнойной и гонококковой этиологии
Ferrer et al. Bactericidal effect of intravitreal levofloxacin in an experimental model of endophthalmitis
Engelbrecht et al. Anti-infective ophthalmic preparations in general practice
Vaninbroukx et al. Preoperative eye disinfection in vitrectomy surgery using antibiotic or antiseptic eyedrops
Tiwari Pharmacological considerations in cataract surgery
Pauli Ecologic impact of broad-spectrum quinolones
Jabran et al. Role of Moxifloxacin in Bacterial Keratitis
Shoaib Update on risk factors and prophylaxis of endophthalmitis after cataract operation
Hariprasad et al. Evidence-Based Medicine: The Prophylaxis and Treatment of Endophthalmitis
Speaker et al. Infectious keratitis
Hariprasad et al. of Endophthalmitis